Read this first

Medical disclaimer

Dose Brief is a newsroom. We report on GLP-1 prices, supply, and the providers behind them.

We are not a pharmacy, a clinic, or your care team. Nothing on this desk is written for your case.

Educational only

Everything we publish is general information for a general audience. It is not medical advice, a diagnosis, or a treatment plan. It does not replace a conversation with a clinician who knows your history.

No care relationship

Reading this site does not make us your doctor. No clinician–patient relationship is formed by visiting, subscribing, or emailing the desk.

Talk to a clinician first

Speak with a licensed clinician before you start, stop, or change any medication or treatment. That includes GLP-1 drugs for weight or diabetes. The decision is a medical one, made with your prescriber.

Results vary

Outcomes differ from person to person. What worked for someone else is not a forecast for you. Side effects, dosing, and results depend on your own health.

Emergencies

This site is not for emergencies. If you think you are having one, call 911 or go to the nearest emergency room.

Compounded GLP-1s

Compounded semaglutide and tirzepatide are not FDA-approved finished drug products. They are not reviewed for safety, quality, or effectiveness the way branded drugs are, and they can differ from Wegovy, Ozempic, or Zepbound. Whether a compounded product is appropriate for you is a call only your prescriber can make.

Provider information

Details about third parties — providers, pharmacies, prices, states served — come from public sources and change fast. Listing a provider is not an endorsement or a recommendation to use them. Confirm anything that matters with the provider and your clinician before you act.

No guarantee

We work to keep the brief accurate, but we cannot guarantee it is complete, current, or error-free. Regulatory status shifts. Prices move. Verify before you rely on anything you read here.